Real-Time Follicle Counting AI Ultrasound Probe Market Global Report 2026

The real-time follicle counting ai ultrasound probe market size has grown rapidly in recent years. It will grow from $0.49 billion in 2025 to $0.55 billion in 2026 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to rising demand for fertility diagnostic solutions, increasing adoption of assisted reproductive technologies, growing incidence of infertility conditions, expanding fertility clinic infrastructure, and increasing need for precise follicle monitoring.

The real-time follicle counting ai ultrasound probe market size is expected to see rapid growth in the next few years. It will grow to $0.91 billion in 2030 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to increasing adoption of AI-powered ultrasound analysis, rising demand for real-time fertility monitoring solutions, growing emphasis on minimizing diagnostic variability, expanding digital transformation across reproductive healthcare, increasing investment in advanced medical imaging technologies. Major trends in the forecast period include growing adoption of AI-based fertility imaging solutions, increasing demand for automated follicle assessment technologies, rising integration of real-time ultrasound diagnostic capabilities, expanding digital reproductive healthcare workflows, increasing focus on enhancing the accuracy of fertility treatments.

The rise in infertility cases globally is expected to propel the growth of the real-time follicle counting AI ultrasound probe market going forward. Infertility is a disease of the male or female reproductive system, defined by the inability to achieve a pregnancy after 12 months or more of regular unprotected sexual intercourse. Globally, infertility cases continue to rise as women increasingly delay childbearing due to career prioritization and changing social norms, reducing natural conception rates among individuals of reproductive age. This growing patient population increases demand for precise, technology-driven fertility diagnostics, and real-time follicle counting AI ultrasound probes directly address this need by enabling clinicians to evaluate ovarian follicle development with greater speed and accuracy, thereby supporting more effective assisted reproductive technology (ART) treatment decisions. For instance, in April 2023, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, approximately 17.5% of the adult population, or about 1 in 6 people globally, experience infertility, emphasizing the urgent need to improve access to affordable, high-quality fertility care for those affected. Therefore, the rise in infertility cases globally is driving the growth of the real-time follicle counting AI ultrasound probe market.

Key companies operating in the real-time follicle counting AI ultrasound probe market are focusing on integrating AI-powered follicle assessment and automation capabilities into ultrasound systems to improve imaging accuracy, streamline fertility workflows, and reduce operator dependency. AI-powered follicle assessment uses deep learning algorithms to automatically detect, count, measure, and monitor ovarian follicles in real time, supporting faster and more consistent fertility evaluations. For example, in January 2025, GE HealthCare Technologies Inc., a US-based medical technology company, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its updated Voluson Expert Series ultrasound systems, including Voluson Expert 22, 20, and 18. The systems incorporate AI-powered automation features, including SonoAVC Follicle 2.0, which enables automated ovarian follicle detection, counting, and measurement to enhance workflow efficiency, imaging performance, and clinical decision-making in fertility assessment and assisted reproductive procedures.

In June 2025, Cycle Clarity, a US-based fertility technology company, entered into a partnership with Artisan to integrate Cycle Clarity’s AI-powered follicular monitoring data and insights directly into Artisan’s electronic medical record platform, facilitating automated data transfer and more efficient fertility clinic operations. Through this collaboration, the companies seek to eliminate manual data entry, enhance access to real-time fertility monitoring information, decrease administrative and nursing workloads, and enable more efficient and individualized patient care. Artisan is a US-based cloud-based technology company that offers electronic medical record solutions specifically developed for fertility practices, supporting clinical operations, patient communication, and integration with ultrasound systems and other fertility-care technologies.

Major companies operating in the real-time follicle counting ai ultrasound probe market are Siemens Healthineers AG, GE HealthCare Technologies Inc., Philips Healthcare, Fujifilm Holdings Corporation, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Canon Medical Systems Corporation, Samsung Medison, Esaote S.p.A., Shenzhen SonoScape Medical Corp., Edan Instruments Inc., CHISON Medical Technologies Co. Ltd., Alpinion Medical Systems Co. Ltd., Butterfly Network Inc., Terason, Clarius Mobile Health Corp., Exo Imaging Inc., Pulsenmore Ltd., Cycle Clarity Inc., Alife Health Inc., VinBrain (VinDr AI)

North America was the dominant region in the real-time follicle counting ai ultrasound probe market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the real-time follicle counting ai ultrasound probe market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the real-time follicle counting ai ultrasound probe market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.